Although the use of sorafenib in patients with treatment-naive metastatic renal cell carcinoma demonstrated clinical benefit, a phase IIb study did not support the use of dose escalation in these patients.
The combination of CB-839, a selective inhibitor of glutaminase, and everolimus seems to have disease activity in patients with advanced renal cell carcinoma.
Metastatic renal cell carcinoma (mRCC) patients who use non-aspirin NSAIDs have poorer overall survival than aspirin users and NSAID non-users, according to a new pooled retrospective analysis.
With a number of therapies now available for treatment of renal cell carcinoma, research is now ongoing to determine the best possible sequencing and potential combinations of those therapies.
The use of proton pump inhibitors does not appear to impact the efficacy of oral VEGF tyrosine kinase inhibitors in metastatic renal cell carcinoma, according to a new study.
A small study found that patients with metastatic renal cell carcinoma (mRCC) who discontinue nivolumab due to immune-related adverse events can continue to derive benefit even after cessation of therapy.
Specific tumor genotypes could represent distinct subtypes of clear cell renal cell carcinoma, according to a new analysis of the RECORD-3 trial. Genotyping could potentially help guide treatment decisions if the results can be validated.
The use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in kidney cancer could offer important new treatment options. Questions remain, though, on the timing and sequence of therapy.
The combination of bevacizumab and an investigational nanoparticle-drug conjugate known as CRLX101 failed to improve outcomes in metastatic renal cell carcinoma compared with standard of care.
Expression of MET as measured by immunohistochemistry was not associated with any difference in the performance of cabozantinib as compared with everolimus in patients with advanced renal cell carcinoma.